• Twitter
  • Jobs
ProCURE oncology
  • HOME
  • ABOUT US
  • RESEARCH GROUP
    • Molleví’s Lab
    • Antolin’s Lab
    • Alemany’s & Piulats’s lab
    • Martínez-Balibrea’s Lab
    • Aytes’s Lab
    • Belver’s Lab
    • Pujana’s Lab
    • Menendez’s Lab
    • Sureda’s & Farre’s Lab
    • Casanovas’s Lab
    • Viñals’s lab
  • INNOVATION
  • NEWS
  • CONTACT
  • Menu Menu

The C Allele of ATM rs11212617 Associates With Higher Pathological Complete Remission Rate in Breast Cancer Patients Treated With Neoadjuvant Metformin

16 de April de 2019
Front Oncol. 2019 Mar 28;9:193. doi: 10.3389/fonc.2019.00193.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2019-04-16 10:00:002019-04-16 10:00:00The C Allele of ATM rs11212617 Associates With Higher Pathological Complete Remission Rate in Breast Cancer Patients Treated With Neoadjuvant Metformin

The extra virgin olive oil phenolic oleacein is a dual substrate-inhibitor of catechol-O-methyltransferase

3 de April de 2019
Food Chem Toxicol. 2019 Jun;128:35-45. doi: 10.1016/j.fct.2019.03.049.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2019-04-03 10:00:002019-04-03 10:00:00The extra virgin olive oil phenolic oleacein is a dual substrate-inhibitor of catechol-O-methyltransferase

Intestinal Permeability Study of Clinically Relevant Formulations of Silibinin in Caco-2 Cell Monolayers

3 de April de 2019
Int J Mol Sci. 2019 Mar 31;20(7):1606. doi: 10.3390/ijms20071606.ABSTRACTAn…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2019-04-03 10:00:002019-04-03 10:00:00Intestinal Permeability Study of Clinically Relevant Formulations of Silibinin in Caco-2 Cell Monolayers

Chemokine (C-C motif) ligand 2 gene ablation protects low-density lipoprotein and paraoxonase-1 double deficient mice from liver injury, oxidative stress and inflammation

26 de March de 2019
Biochim Biophys Acta Mol Basis Dis. 2019 Jun 1;1865(6):1555-1566.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2019-03-26 10:00:002019-03-26 10:00:00Chemokine (C-C motif) ligand 2 gene ablation protects low-density lipoprotein and paraoxonase-1 double deficient mice from liver injury, oxidative stress and inflammation

The moonlighting RNA-binding activity of cytosolic serine hydroxymethyltransferase contributes to control compartmentalization of serine metabolism

28 de February de 2019
Nucleic Acids Res. 2019 May 7;47(8):4240-4254. doi: 10.1093/nar/gkz129.ABSTRACTEnzymes…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2019-02-28 11:00:002019-02-28 11:00:00The moonlighting RNA-binding activity of cytosolic serine hydroxymethyltransferase contributes to control compartmentalization of serine metabolism

Treating atherosclerosis: targeting risk factors should not be the only option

8 de January de 2019
Ann Transl Med. 2018 Nov;6(Suppl 1):S34. doi: 10.21037/atm.2018.09.40.NO…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2019-01-08 11:00:002019-01-08 11:00:00Treating atherosclerosis: targeting risk factors should not be the only option

A phase 2 trial of neoadjuvant metformin in combination with trastuzumab and chemotherapy in women with early HER2-positive breast cancer: the METTEN study

28 de November de 2018
Oncotarget. 2018 Nov 2;9(86):35687-35704. doi: 10.18632/oncotarget.26286.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2018-11-28 11:00:002018-11-28 11:00:00A phase 2 trial of neoadjuvant metformin in combination with trastuzumab and chemotherapy in women with early HER2-positive breast cancer: the METTEN study

Metformin Is a Direct SIRT1-Activating Compound: Computational Modeling and Experimental Validation

22 de November de 2018
Front Endocrinol (Lausanne). 2018 Nov 6;9:657. doi: 10.3389/fendo.2018.00657.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2018-11-22 11:00:002018-11-22 11:00:00Metformin Is a Direct SIRT1-Activating Compound: Computational Modeling and Experimental Validation

An olive oil phenolic is a new chemotype of mutant isocitrate dehydrogenase 1 (IDH1) inhibitors

15 de November de 2018
Carcinogenesis. 2019 Mar 12;40(1):27-40. doi: 10.1093/carcin/bgy159.ABSTRACTMutations…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2018-11-15 11:00:002018-11-15 11:00:00An olive oil phenolic is a new chemotype of mutant isocitrate dehydrogenase 1 (IDH1) inhibitors

Influence of age and spectral power distribution on mesopic visual sensitivity

1 de November de 2018
Atten Percept Psychophys. 2019 Feb;81(2):504-516. doi: 10.3758/s13414-018-1616-6.ABSTRACTThe…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2018-11-01 10:00:002018-11-01 10:00:00Influence of age and spectral power distribution on mesopic visual sensitivity

Plasma Energy-Balance Metabolites Discriminate Asymptomatic Patients with Peripheral Artery Disease

18 de October de 2018
Mediators Inflamm. 2018 Sep 20;2018:2760272. doi: 10.1155/2018/2760272.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2018-10-18 10:00:002018-10-18 10:00:00Plasma Energy-Balance Metabolites Discriminate Asymptomatic Patients with Peripheral Artery Disease

Immune-related adverse events and atypical radiological response with checkpoint inhibitor immunotherapy in an elderly patient with high PD-L1 expressing lung adenocarcinoma

26 de September de 2018
Oncotarget. 2018 Aug 31;9(68):33043-33049. doi: 10.18632/oncotarget.25984.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2018-09-26 10:00:002018-09-26 10:00:00Immune-related adverse events and atypical radiological response with checkpoint inhibitor immunotherapy in an elderly patient with high PD-L1 expressing lung adenocarcinoma
Page 8 of 11«‹678910›»

Filter by categories

  • Alemany’s & Piulats’s lab (131)
  • Antolin's lab (36)
  • Aytes's Lab (24)
  • Belver's Lab (25)
  • Casanovas's Lab (77)
  • Martínez-Balibrea's Lab (43)
  • Menendez's Lab (121)
  • Molleví's Lab (35)
  • Pujana's Lab (110)
  • Sureda's & Farre's Lab (259)
  • Viñals's lab (111)

Twitter

Tweets by ProcureICO
Program Against Cancer Therapeutic Resistance

CONTACT US

Campus IDIBELL
(L’Hospitalet del Llobregat)
Hospital Duran i Reynals, Gran Via 199,
L’Hospitalet del Llobregat,
Barcelona 08908
Tel. +34 93 260 7952

Campus IGTP-IJC
(Badalona)
Campus Can Ruti – IGTP – Building Muntanya,
Rd. Can Ruti, Camí de les escoles s/n,
Badalona, Barcelona 08916
Tel. +34 93 554 3069

Campus IDIBGI
(Girona)
Parc Hospitalari Martí i Julià de Salt, Dr. Castany s/n,
Salt, Girona 17190
Tel. +34 872 987 087

© Copyright - Edisenius
  • Privacy Policy
  • Cookie Policy
  • Legal Notice
Scroll to top
Manage cookie consent
To offer the best experiences, we use technologies such as cookies to store and/or access device information. Consent to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Failure to consent, or withdrawal of consent, may adversely affect certain features and functions.
Functional Always active
Storage or technical access is strictly necessary for the legitimate purpose of allowing the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. Storage or technical access that is used exclusively for anonymous statistical purposes. Without a requirement, voluntary compliance by your Internet service provider, or additional records from a third party, information stored or retrieved solely for this purpose cannot be used to identify you.
Marketing
Storage or technical access is necessary to create user profiles to send advertising, or to track the user on a website or several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
See preferences
{title} {title} {title}